[Epidemiology and COPD screening in France. Workshop from the Société de Pneumologie de Langue Française (SPLF)].
BACKGROUND
A workshop has been organized in April 2013 by the Société de Pneumologie de Langue Française about COPD epidemiology and COPD screening in France and other European countries. This article deals with epidemiological data and their consequences on the French screening strategy.


BACKGROUND
According to the most recent data, spirometric prevalence of COPD in France is 7.5% in individuals over 45 years old. During 2000-2002, COPD was responsible for 1.4% of all causes of death in France and was mentioned to be an associated cause of death in 3% of all death certificates. The average medical costs for one COPD patient is estimated to be 4366 €/year, until 7502 €/year in very severe COPD patients. All clinical studies that have been performed in France show that COPD screening via mini-spirometry is feasible in general practice or in an ambulatory setting; however, a mass screening proved to be difficult to perform. A simple technique like the Piko-6(®) implies a concomitant formalized training. The non-reimbursement by the French Social Security is also a limiting factor, as the absence of medical and economical validation of this strategy. Therefore, COPD screening should be focused to individuals at risk and should include tobacco issues and cessation.


CONCLUSIONS
COPD screening strategies have to be medically evaluated and experiments have to take the specificities of the French health organization into consideration. Any COPD screening strategy should be considered as an overall fight against the tobacco epidemics.
Unité de soins intensifs respiratoires, service de pneumologie, CHU de Rouen et UPRES EA 3830, institut hospitalo-universitaire de recherche biomédicale, université de Rouen, 76031 Rouen cedex, France. Electronic address: maxime.patout@icloud.com.
M
M
Patout
Service de pneumologie, hôpitaux de Brabois, CHU de Nancy, 54500 Vandœuvre-lès-Nancy, France.
M
M
Zysman
Laboratoire santé, travail, environnement, service des maladies respiratoires, CHU de Bordeaux, institut de santé publique, d'épidémiologie et de développement (ISPED), université Bordeaux 2, 33076 Bordeaux cedex, France.
C
C
Raherison Semjen
Service de pneumologie, hôpital Calmette, CHRU, 59000 Lille, France.
T
T
Perez
Unité de soins intensifs respiratoires, service de pneumologie, CHU de Rouen et UPRES EA 3830, institut hospitalo-universitaire de recherche biomédicale, université de Rouen, 76031 Rouen cedex, France.
A
A
Cuvelier
Service de pneumologie et soins intensifs respiratoires, groupe hospitalier Cochin-Broca - Hôtel-Dieu, université Paris Descartes, 75005 Paris, France.
N
N
Roche
D000368:Aged; D003226:Congresses as Topic; D004493:Education; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000706:statistics & numerical data; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis* / Q000453:epidemiology*
Analyse coût-efficacité; Bronchopneumopathie chronique obstructive; Chronic obstructive pulmonary disease; Cost-benefit analysis; Dépistage; Epidemiology; Mortality; Mortalité; Screening; Épidémiologie